MetaCap

Immunic (IMUX) vs Jyong Biotech (MENS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immunic (IMUX) has outperformed Jyong Biotech (MENS) over the past year, gaining 1.9% versus a loss of 95.3%. Immunic is the larger company by market cap ($111.0 million vs $110.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMUX+1.90%MENS-95.28%
+158%+26%-107%
Nov 21, 20251 yearNov 20, 2026
IMUX-2.92%MENS-81.90%
+759%+319%-122%
Jun 16, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMUX versus MENS key metrics
MetricIMUXMENS
Share price$6.99$1.45
Market cap$111.01M$110.24M
1-day change-5.41%-17.14%
YTD return+30.90%-63.29%
1-year return+1.90%-95.28%
5-year return-91.88%—
EPS (TTM)$-3.53$-0.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-97.17M$-4.67M
52-week high$17.43$38.88
52-week low$5.06$1.43
Distance from 52-week high-59.90%-96.27%
Analyst consensusstrong_buy—
Avg. price target upside+508.73%—
Average volume343.44K44.23K
Shares outstanding15.88M74.23M
Employees10027
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMUX has outperformed MENS by 97.2 percentage points over the past year.

About Immunic

IMUX stock →

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Jyong Biotech

MENS stock →

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

IMUX vs MENS FAQ

Which is bigger, Immunic or Jyong Biotech?

Immunic (IMUX) is larger, with a market capitalization of $111.01M compared with $110.24M for Jyong Biotech (MENS).

Which stock has performed better over the past year, IMUX or MENS?

IMUX returned +1.90% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.

Are Immunic and Jyong Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons